BioLineRx Ltd.
Длинная
Обновлено

BLRX-BREAKOUT-UPDATE

389
BLRX had a strong rally today and it's just getting started.

In the related idea my price target was $1.34.

Today's high was $1.78

Check out the weekly chart:

снимок

Photo Finish.

$1.34 was 1.618 extension level from Waves 1 & 2.

Since the price-action broke $1.34 we will have an extended 3rd wave.

I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.

Target is hard to predict since its impossible to know what level extending waves will terminate.

I will keep a close eye on the price-action.

Will update.

-AB






Заметка
As expected, a very strong rally today!
Заметка
снимок
Заметка
We got a big runway...
Заметка
Reminder this is a WEEKLY chart...

Meaning this move is far from over...
Заметка
снимок
Заметка
Buckle up!
Заметка
снимок
Заметка
Target $2.24 (Sell Half)

Trade Price: 1.049
Заметка
снимок
Заметка
снимок
Заметка
Bull Flag
Заметка
BLRX will rally again tomorrow.
Заметка
снимок
Заметка
BLRX is about to rally again...
Заметка
BLRX continued to consolidate today.

Staying the course...
Заметка
снимок
Заметка
снимок
Заметка
Near-Term Target: $2.13
Заметка
снимок
Заметка
Primary Wave 1 Complete
Заметка
снимок
Заметка
03:21 PM EDT, 10/22/2018 (MT Newswires) -- Oppenheimer has kept its outperform rating on BioLineRx (BLRX) with a price target of $3, betting on BL-8040's commercial opportunity as a stem cell mobilizer after top-line data from the COMBAT/KEYNOTE-202 trial of BL-8040 in combination with pembrolizumab in advanced pancreatic cancer showed modest response rate.
"Given the combination's favorable safety profile, BioLineRx and Merck (MRK) are testing a triplet combination including chemotherapy in an effort to increase response rate," analyst Mark Breidenbach said in a note.
"While we believe the triplet combination is worth testing, our valuation of BioLineRx still remains focused on BL-8040's commercial opportunity as a stem cell mobilizer."
Заметка
снимок
Заметка
снимок
Заметка
Breakout Imminent
Заметка
снимок

Отказ от ответственности

Информация и публикации не предназначены для предоставления и не являются финансовыми, инвестиционными, торговыми или другими видами советов или рекомендаций, предоставленных или одобренных TradingView. Подробнее читайте в Условиях использования.